Since the last time I wrote about immunology treatment provider AbbVie Inc. (NYSE: ABBV ) in April, its price hasn't moved much at all, with sub-2% gains. But short-term gains weren't the impetus behind the Buy rating on the stock anyway. It wasManika is a macroeconomist with over 20 years of experience in industries including investment management, stock broking, investment banking. She also runs the profile Long Term Tips [LTT], which focuses on the generational opportunity in the green economy. Her inves ...

Dublin, July 22, 2025 (GLOBE NEWSWIRE) -- The "Catalyst Monitor: Q3 2025 Outlook" report has been added to ResearchAndMarkets.com's offering.The report delivers forward-looking intelligence derived from interviews with key opinion leaders (KOLs), covering trial initiations, completions, top-line results, regulatory filings, PDUFA dates, and expected approvals. The report covers 18 significant catalyst events that are expected to occur in Q3 2025. Some of the catalysts covered in the report, include FDA app ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Zacks ...

Key Takeaways ALKS' alixorexton met primary goals in the phase II Vibrance-1 study for narcolepsy type 1. The 6 mg dose was the only one to meet a key secondary goal on cataplexy rates in the study. ALKS plans a global phase III trial as it eyes broader use of alixorexton in sleep disorders.Alkermes (ALKS) announced positive top-line data from the phase II Vibrance-1 study, which evaluated its novel, investigational, and oral orexin 2 receptor agonist, alixorexton (formerly ALKS 2680), for treating patien ...

Key Takeaways ABBV's neuroscience franchise is expected to generate $2.5 billion in Q2, up 15% year over year. Growth likely driven by Botox Therapeutic, Vraylar and market share gains for Qulipta and Ubrelvy. Newly launched Vyalev may contribute modest U.S. sales, with most revenues from international markets.AbbVie (ABBV) holds a leadership position in the neuroscience space, which encompasses blockbuster medications such as Botox Therapeutic and depression drug Vraylar. Over the years, the company has ...

CVS Health (CVS) has been on a downward spiral lately with significant selling pressure. After declining 7.7% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscilla ...

Core Insights - Value investing focuses on identifying stocks trading below their intrinsic value, allowing investors to benefit as market prices align with true company value over time [1] - Earnings yield, calculated as earnings per share divided by stock price, is a useful metric for identifying undervalued stocks, with a higher yield indicating potential undervaluation [2][4] - A screening criterion of an earnings yield greater than 10% is established, alongside other parameters like estimated EPS growth and average daily volume [6][7] Company Highlights - IAMGOLD Corporation (IAG) is a gold exploration and mining company with projected earnings growth of 44% and 40% for 2025 and 2026, respectively, and currently holds a Zacks Rank 1 [9] - Plains GP Holdings (PAGP) is involved in crude oil and refined products transportation, with earnings growth estimates of 206% and 24% for 2025 and 2026, respectively, also holding a Zacks Rank 1 [10][11] - Hope Bancorp (HOPE) provides commercial banking services, with earnings growth estimates of 12% and 40% for 2025 and 2026, and holds a Zacks Rank 1 [12] - CommScope Holding Company, Inc. (COMM) offers communication network infrastructure solutions, with an extraordinary earnings growth estimate of 3,167% for 2025 and 28% for 2026, holding a Zacks Rank 2 [13] - Harmony Biosciences Holdings Inc. (HRMY) focuses on therapies for rare neurological disorders, with earnings growth estimates of 22% and 32% for 2025 and 2026, and holds a Zacks Rank 2 [14]

Core Insights - The Price-to-Book (P/B) ratio is a valuation metric that compares a company's market capitalization to its book value, helping investors identify undervalued stocks with strong fundamentals [1][2][6] - The P/B ratio is particularly useful in value investing, where investors seek stocks that are cheap yet fundamentally strong [1][10] - A P/B ratio of less than one indicates that a stock is trading below its book value, suggesting it may be undervalued, while a ratio above one may indicate overvaluation [6][8] Understanding Book Value - Book value represents the total value remaining for shareholders if a company were to liquidate its assets after settling all liabilities [4][5] - It is calculated by subtracting total liabilities from total assets, often equating to common stockholders' equity [5] P/B Ratio Analysis - The P/B ratio is calculated as market capitalization divided by book value of equity, providing insight into whether a stock is under- or overvalued [2][6] - Stocks with low P/B ratios and strong projected earnings growth are considered attractive investment opportunities [10][16] Screening Parameters for Investment - Stocks should have a P/B ratio lower than the industry median, a P/S ratio below the industry average, and a P/E ratio using F(1) estimates that is also lower than the industry median [12][13] - A PEG ratio of less than 1 indicates that a stock is undervalued relative to its growth prospects, while a minimum trading price of $5 and a substantial average trading volume are also recommended [14][15] Notable Stocks with Low P/B Ratios - CVS Health (CVS) has a projected 3-5 year EPS growth rate of 11.4% and holds a Zacks Rank of 2 with a Value Score of A [16] - Signet Jewelers (SIG) has a projected EPS growth rate of 12.2% and also holds a Zacks Rank of 2 with a Value Score of A [17] - KB Financial Group (KB) has a projected EPS growth rate of 12.33% and a Zacks Rank of 2 with a Value Score of B [18] - Affiliated Managers Group (AMG) has a projected EPS growth rate of 14.2% and a Zacks Rank of 2 with a Value Score of A [19] - PagSeguro Digital (PAGS) has a projected EPS growth rate of 11.3% and holds a Zacks Rank of 1 with a Value Score of A [21]

AstraZeneca said Tuesday it's planning to invest $50 billion in expanding its manufacturing and research presence in the U.S. by 2030, as worries about tariffs loom over the industry. https://t.co/MYmPLMR2Jq ...

医药行业25Q2基金持仓分析 ——药基/非药基医药重仓占比持续回升，创新药为共 识度最高的加仓方向 行业研究报告|行业专题报告 医药生物 行业评级 强于大市（维持评级） 2025年7月22日 证券分析师： 陈铁林 执业证书编号：S0210524080007 联系人： 何展聪 请务必阅读报告末页的重要声明 华福证券 华福证券 核心观点 ➢ 25Q2医药板块基金持仓整体情况： ➢ Q2医药行业基金重仓占比回升： 25Q2全部公募基金的医药重仓占比为9.8%，环比+0.7pct，超配比例为3.36%，环比+0.5pct； 25Q2全部公募主动基金的医药重仓占比为11%，环比+1.4pct，超配比例为4.62%，环比+1.3pct； 25Q2全部非药基金的医药重仓占比为4.6%，环比+0.5pct，低配比例为-1.85%，环比+0.3pct； 25Q2全部非药主动基金的医药重仓占比为6.0%，环比+1.1pct，低配比例为-0.37%，环比+0.9pct。 ➢ 资金结构：主动基金重仓市值占比和规模占比均有所提升。 2 华福证券 华福证券 25Q2医药主动基金重仓市值占医药整体重仓市值的比例为32%，环比-0.7pct ...